

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-3. (Canceled)

4. (Previously presented) A peptide that binds  $\alpha 3\beta 1$  integrin, wherein said peptide consists of a sequence selected from the group consisting of FQGVLLQVRFVF (SEQ ID NO:20), FQGVLSVRFVF (SEQ ID NO:21), acQGVLNVRVF (SEQ ID NO:22), FQGVLLNVRVFVF (SEQ ID NO:24), AQGVLNVRVFVF (SEQ ID NO:25), FAGVLQNVRFVF (SEQ ID NO:26), FQGVAQNVRFVF (SEQ ID NO:27), FQGVLLQNVRFVA (SEQ ID NO:28), FQGVLANVRVFVF (SEQ ID NO:29), FQGVLLQNVRFV (SEQ ID NO:30), QGVLLQNVRFVF (SEQ ID NO:31), and FQGVLLQNVRF (SEQ ID NO:32).

5. (Currently amended) A peptide consisting of the sequence  $R_1$ - $X_1$ - $X_2$ - $X_3$ - $X_4$ - $R_2$  or full retro-inverso sequences thereof, wherein  $X_1$  is selected from the group consisting of N and Q;  $X_2$  is V;  $X_3$  is R; and  $X_4$  is F;  $R_1$  is a hydrogen or from 1 to 6 amino acids, an acyl or an aryl group; and  $R_2$  is from 1 to 3 amino acids, a hydroxide or an amide, provided that the peptide binds  $\alpha 3\beta 1$  integrin, and wherein the  $X_1$ - $X_2$ - $X_3$ - $X_4$  portion of the sequence is optionally selected from the group consisting of NVRF (SEQ ID NO:51) and or QVRF (SEQ ID NO:53).

6-9. (Canceled)

10. (Previously presented) A peptide consisting of the sequence FQGVLLQNVRFVF (SEQ ID NO:6) wherein every amino acid in said sequence is a D-amino acid.

11-12. (Canceled)

13. (Currently amended) A composition comprising a peptide according to ~~claim 1~~ claim 5 and a pharmaceutically acceptable carrier.

14. (Previously presented) A composition comprising a peptide according to ~~claim 1~~ claim 5 in a sterile aqueous solution.

15-19. (Canceled)

20. (Currently amended) An *in vitro* method of inhibiting adhesion of a cell expressing  $\alpha 3 \beta 1$  integrin to an extracellular matrix comprising contacting said cell with a peptide according to ~~claim 1~~ claim 5.

21. (Withdrawn) The method of claim 20 wherein the extracellular matrix comprises TSP1 or laminins.

22. (Cancel)

23. (Withdrawn) The method of claim 20 wherein said cell comprises an epithelial or an endothelial cell.

24. (Withdrawn) The method of claim 20 wherein said cell is a tumor cell.

25. (Withdrawn) The method of claim 20 wherein said cell is a breast carcinoma cell or a small cell lung carcinoma.

26. (Currently amended) An *in vitro* method of inhibiting  $\alpha\beta 1$  integrin-mediated cell motility, comprising contacting a cell with a peptide according to ~~claim 1~~ claim 5.

27. (Canceled)

28. (Withdrawn) The method of claim 26 wherein the cell is an epithelial cell, an endothelial cell or a malignant cell.

29. (Currently amended) An *in vitro* method of inhibiting proliferation of endothelial cells, comprising contacting said cells with a peptide according to ~~claim 1~~ claim 5.

30. (Currently amended) An *in vitro* method of inhibiting proliferation of small cell lung carcinoma cells, comprising contacting said cells with a peptide according to ~~claim 2~~ claim 5.

31-45. (Canceled)

46. (Previously presented) A peptide consisting of the sequence  $R_1-X_1-X_2-X_3-X_4-R_2$  or full retro-inverso sequences thereof, wherein  $X_1$  is D;  $X_2$  is V;  $X_3$  is R; and  $X_4$  is F;  $R_1$  is a hydrogen or from 1 to 6 amino acids, an acyl or an aryl group; and  $R_2$  is 2 or 3 amino acids, a hydroxide or an amide, provided that the peptide binds  $\alpha\beta 1$  integrin.

47. (Previously presented) The peptide according to claim 46 consisting of the sequence FQGVLQDVRVVF (SEQ ID NO:19).

48. (Previously presented) The peptide of claim 46, wherein the peptide contains the sequence DVRVF (SEQ ID NO:54) and is up to 12 amino acids in length.

49. (Previously presented) The peptide of claim 46 wherein R<sub>1</sub> is a peptide consisting of the sequence selected from the group consisting of FQGV<sub>1</sub>LQ (SEQ ID NO:13), FAGVLQ (SEQ ID NO:14), FQGV<sub>1</sub>AQ (SEQ ID NO:15), FQGV<sub>1</sub>LA (SEQ ID NO:16), and FQGV<sub>1</sub>LN (SEQ ID NO:17).

50. (Previously presented) The peptide of claim 46 that contains at least one D-amino acid.

51. (Previously presented) A composition comprising a peptide according to claim 46 and a pharmaceutically acceptable carrier.

52. (Previously presented) A composition comprising a peptide according to claim 46 in a sterile aqueous solution.

53. (Previously presented) A retro-inverso synthetic peptide consisting of the amino acid sequence, from C-terminal (left) to N-terminal (right): ri- R'<sub>1</sub>-D-V-R-F-R'<sub>2</sub>, wherein ri denotes a retro-inverso peptide sequence and all amino acids are D amino acids and D-V-R-F is SEQ ID NO:54; R'<sub>1</sub> is a hydrogen or from 1 to 6 amino acids, a hydroxide or an amide; and R'<sub>2</sub> is 2 or 3 amino acids, a hydroxide or an amide, provided that the peptide binds  $\alpha 3\beta 1$  integrin.

54. (Previously presented) The peptide of claim 46, wherein the peptide contains the sequence DVRF (SEQ ID NO:54) and is up to 12 amino acids in length.